"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 3 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 8 | 8 |
| 2003 | 5 | 2 | 7 |
| 2004 | 6 | 3 | 9 |
| 2005 | 5 | 5 | 10 |
| 2006 | 4 | 3 | 7 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 4 | 8 |
| 2009 | 10 | 3 | 13 |
| 2010 | 18 | 8 | 26 |
| 2011 | 18 | 9 | 27 |
| 2012 | 15 | 8 | 23 |
| 2013 | 9 | 7 | 16 |
| 2014 | 16 | 5 | 21 |
| 2015 | 9 | 3 | 12 |
| 2016 | 13 | 11 | 24 |
| 2017 | 13 | 10 | 23 |
| 2018 | 7 | 8 | 15 |
| 2019 | 7 | 10 | 17 |
| 2020 | 11 | 8 | 19 |
| 2021 | 6 | 14 | 20 |
| 2022 | 1 | 16 | 17 |
| 2023 | 1 | 9 | 10 |
| 2024 | 6 | 13 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
-
Psychosocial outcomes with the Omnipod? 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. Diabetes Obes Metab. 2024 Dec; 26(12):5569-5579.
-
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. J Am Coll Cardiol. 2024 Aug 20; 84(8):696-708.
-
Impact of Antihyperglycemic Drugs on Asthma Outcomes: Diversifying the Research Portfolio. J Allergy Clin Immunol Pract. 2024 Aug; 12(8):2045-2046.
-
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? Curr Cardiol Rep. 2024 Sep; 26(9):1011-1019.
-
Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema. J Diabetes Complications. 2024 Aug; 38(8):108808.
-
Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model. Am J Obstet Gynecol. 2024 Sep; 231(3):352.e1-352.e16.
-
Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. J Clin Endocrinol Metab. 2024 Apr 19; 109(5):1361-1370.
-
Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Tex Heart Inst J. 2024 Apr 09; 51(1).
-
Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity? Gut. 2024 04 05; 73(5):721-724.